398 Characterization of the Inactive Hbsag Carrier State With 3 Year Follow-Up

Yakut, Mustafa; Bektaş, Mehmet; Seven, Gülseren; Kabaçam, Gökhan; Karataylı, Ersin; Karataylı, Senem Ceren; Bozdayı, A. Mithat; Idilman, R.; Yurdaydın, Cihan

doi:10.1016/s0168-8278(11)60400-5

Cited by 11 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In conclusion, the recent studies have emphasized that detection of HBsAg <1000 or ≤2000 IU/mL are significant along with normal ALT levels and HBV DNA ≤2000 IU/mL to differentiate inactive carriers from patients with HBeAg negative chronic hepatitis B (10,11). In our study, the most appropriate quantitative HBsAg value has been found as 2147 IU/mL for defining inactive carriers (with the sensitivity of 76% and specificity of 70%).…”

Section: -Specificity Sensitivitysupporting

confidence: 47%

Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection

Günal¹,

Barut²,

Etikán³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: In this study, we aimed to investigate whether quantitative HBsAg and alanine aminotransferase (ALT) levels correlated with Hepatitis B Virus (HBV) DNA levels in patients with HBeAg negative chronic HBV infection. Materials and Methods: Ninetynine patients were divided into two groups; inactive HBsAg carriers (IC) and active carriers (AC) with HBV DNA >2000 IU/mL. These two groups were compared in terms of ALT and HBsAg levels. Quantitative HBsAg measurements were performed with Elecsys HBsAg II Quant assay (Roche Diagnostic) Results: Mean age of patients was 43.11±14.79 years. HBsAg and ALT values of IC and AC patients were 2.47±1.35 log10 IU/mL, 3.59±0.97log10 IU/mL (p=0.0001), and 25.94±13.06 IU/mL, 55.54±82.38 IU/mL (p=0.015), respectively and the difference was significant. When ROC analysis was performed to determine the most appropriate quantitative HBsAg value to define inactive carrier patients, the area under the ROC curve for HBsAg was 0.738 (95% CI:0.637-0.840). A cut-off of 2147 IU/mL revealed sensitivity of 76% and specificity of 70% for diagnosing the IC. Also, a significant correlation was also found between levels of HBV DNA (log) and HBsAg (log) (r: 0.503, p=0.0001). Conclusion: It has been concluded that quantitative measurements of HBsAg could be used to differentiate between IC and AC patients.

show abstract

Section: -Specificity Sensitivitysupporting

confidence: 47%

Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection

Günal¹,

Barut²,

Etikán³

et al. 2015

Turk J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Overall, 32 patients had HBsAg 62000 IU/ml and HBV DNA 62000 IU/ml, and all were ''inactive carriers'' (PPV 100%). Similarly, one recent Turkish study found that an HBsAg level of 2040 IU/ml best defined inactive carriers from chronic hepatitis patients during a 3-year follow-up (sensitivity 87.2%, specificity 75.3%) [44].…”

Section: Current Evidencementioning

confidence: 82%

Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report

Chan

Thompson

Martinot–Peignoux

et al. 2011

Journal of Hepatology

292

272

View full text Add to dashboard Cite

Quantitative HBsAg had been suggested to be helpful in management of HBV, but assays were cumbersome. The recent availability of commercial quantitative assays has restarted the interest in quantitative serum hepatitis B surface antigen (HBsAg) as a biomarker for prognosis and treatment response in chronic hepatitis B. HBsAg level reflects the transcriptional activity of cccDNA rather than the absolute amount of cccDNA copies. Serum HBsAg level tends to be higher in hepatitis B e antigen (HBeAg)-positive than HBeAg-negative patients. Among patients with a low HBV DNA (<2000IU/ml), HBsAg <1000IU/ml in genotype D HBV infection and HBsAg <100IU/ml in genotype B/C HBV infection is associated with inactive carrier state in HBeAg-negative patients. The HBsAg reduction by nucleos(t)ide analogues (NA) is not as pronounced as by interferon treatment. On peginterferon treatment, sustained responders tend to show greater HBsAg decline than the non-responders. The optimal on-treatment HBsAg cutoff to predict response needs further evaluation in HBeAg-positive patients, but an absence of HBsAg decline together with a <2 log reduction in HBV DNA at week 12 can serve as stopping rule in HBeAg-negative patients with genotype D HBV infection. A rapid serum HBsAg decline during NA therapy may identify patients who will clear HBsAg in the long-term. There are early reports among Asian patients that an HBsAg level of <100IU/ml might predict lower risk of relapse after stopping NA treatment. In clinical practice, serum HBsAg level should be used together with, but not as a substitute for, HBV DNA.

show abstract

“…The inactive carrier state was defined based on existing knowledge. These patients had been followed at the ambulatory Clinic of the Gastroenterology Department of Ankara University Medical School for three monthly visits for more than a year and the majority of them were recruited from a prospective followed study cohort . These patients had to have normal ALT and low or undetectable HBV DNA.…”

Section: Methodsmentioning

confidence: 99%

Interleukin‐28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg‐negative chronic hepatitis B

Karataylı

Bozdayı

Karataylı

et al. 2014

Liver International

View full text Add to dashboard Cite

show abstract

398 Characterization of the Inactive Hbsag Carrier State With 3 Year Follow-Up

Cited by 11 publications

References 0 publications

Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection

Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection

Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report

Interleukin‐28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg‐negative chronic hepatitis B

Contact Info

Product

Resources

About